Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: Implications for HIV-1 vaccine efficacy trials

被引:0
|
作者
Baeten, JM
Richardson, BA
Martin, HL
Nyange, PM
Lavreys, L
Ngugi, EN
Mandaliya, K
Ndinya-Achola, JO
Bwayo, JJ
Kreiss, JK
机构
[1] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA
[2] Univ Washington, Dept Biostat, Seattle, WA 98104 USA
[3] Univ Washington, Dept Med, Seattle, WA 98104 USA
[4] Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya
[5] Univ Nairobi, Dept Community Hlth, Nairobi, Kenya
[6] Coastal Prov Gen Hosp, Mombasa, Kenya
关键词
HIV-1; incidence; vaccine; prostitutes; sexual behavior; STD; Africa;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Accurate predictions of HIV-1 incidence in potential study populations are essential for designing HIV-1 vaccine efficacy trials. Little information is available on the estimated incidence of HIV-I in such populations, especially information on incidence over time and incidence while participating in risk-reduction programs. Objectives: To examine time trends in HIV-1 incidence in a vaccine preparedness cohort. Design: Prospective cohort study of female prostitutes in Mombasa, Kenya. Methods: HIV-1 incidence was determined using open and closed cohort designs. Generalized estimating equations were used to model HIV-1 and sexually transmitted disease (STD) incidence and sexual risk behaviors over time. Results: When analyzed as a closed cohort, HIV-1 incidence declined 10-fold during 3 years of follow-up (from 17.4 to 1.7 cases/100 person-years; p <.001). More than 50% of the cases of HIV-1 occurred during the first 6 months after enrollment, and 73% during the first 12 months. When analyzed as an open cohort, HIV-1 incidence density fell during the first 4 calendar years, influenced by accumulation of lower risk participants and variations in study recruitment. Significant declines occurred in both STD incidence and high-risk sexual behaviors during follow-up. Conclusions: This study documents a dramatic decline in the risk of HIV-1 infection while participating in a prospective cohort, with most seroconversions occurring within 1 year of enrollment. Variations in HIV-1 incidence within high-risk populations should be anticipated during the design of vaccine trials.
引用
收藏
页码:458 / 464
页数:7
相关论文
共 50 条
  • [1] Accelerating HIV-1 Vaccine Efficacy Trials
    Barouch, Dan H.
    Michael, Nelson L.
    [J]. CELL, 2014, 159 (05) : 969 - 972
  • [2] Lessons from HIV-1 vaccine efficacy trials
    Excler, Jean-Louis
    Michael, Nelson L.
    [J]. CURRENT OPINION IN HIV AND AIDS, 2016, 11 (06) : 607 - 613
  • [3] Sieve analysis in HIV-1 vaccine efficacy trials
    Edlefsen, Paul T.
    Gilbert, Peter B.
    Rolland, Morgane
    [J]. CURRENT OPINION IN HIV AND AIDS, 2013, 8 (05) : 432 - 436
  • [4] HIV-1 infection and prostitutes
    Tirelli, U
    Spina, M
    [J]. LANCET, 1998, 351 (9110): : 1214 - 1214
  • [5] Preexisting Adenovirus Seropositivity Is Not Associated With Increased HIV-1 Acquisition in Three HIV-1 Vaccine Efficacy Trials
    Stephenson, Kathryn E.
    Hural, John
    Buchbinder, Susan P.
    Sinangil, Faruk
    Barouch, Dan H.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2012, 205 (12): : 1806 - 1810
  • [6] Should South Africa be preparing for HIV-1 vaccine efficacy trials?
    Morris, L
    vanderRyst, E
    Gray, C
    [J]. SOUTH AFRICAN MEDICAL JOURNAL, 1997, 87 (03): : 285 - 290
  • [7] Insights from HIV-1 vaccine and passive immunization efficacy trials
    Ahmed, Shamim
    Herschhorn, Alon
    [J]. TRENDS IN MOLECULAR MEDICINE, 2024, 30 (10) : 908 - 912
  • [8] Complex immune correlates of protection in HIV-1 vaccine efficacy trials
    Tomaras, Georgia D.
    Plotkin, Stanley A.
    [J]. IMMUNOLOGICAL REVIEWS, 2017, 275 (01) : 245 - 261
  • [9] Preexisting Immunity to Multiple Adenovirus Serotypes is Not Associated with Increased HIV-1 Acquisition in Three HIV-1 Vaccine Efficacy Trials
    Stephenson, K. E.
    Hural, J.
    Buchbinder, S. P.
    Sinangil, F.
    Barouch, D. H.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A132 - A133
  • [10] HIV-1 superinfections: omens for vaccine efficacy?
    Fultz, PN
    [J]. AIDS, 2004, 18 (01) : 115 - 119